Growth of advanced cell therapy fueled by trials outside has recently completed our trials compilation for the first quarter of 2018 (Jan-Feb-Mar) and we compare this time period to the first quarter of 2017:

  • Overall number of trials increased 35% from 2017Q1 to 2018Q1.
  • Current trials breakdown 53% Immunotherapy / 47% Regenerative Medicine.
  • Growth of trials registered on is less than 10%.
  • Growth of trials only registered outside is more than double.
  • Outside trials include registries in China, Japan, India, Iran and Australia.

Growth trials 2017Q1 to 2018Q1

These comments are submitted by website readers and are not endorsed by, which is a project of Parent's Guide to Cord Blood Foundation. We screen the comments to keep out SPAM but we cannot review each one for accuracy.